Although knowledge about chemerin, elafin, and visfatin/NAMPT in AD is growing, the inherent complexity and heterogeneity of the disease, combined with inconsistencies in study methodology, pose serious obstacles to drawing clear, comparable, and reproducible conclusions from scientific studies. This evidence concerns the gene NAMPT and Alzheimer disease.